JPMorgan Upgrades Recursion Pharmaceuticals (RXRX.US) to "Overweight," Citing Blockbuster Potential for Core Asset REC-4881

Stock News12-18 14:31

JPMorgan has upgraded Recursion Pharmaceuticals (RXRX.US) from "Neutral" to "Overweight," citing the blockbuster sales potential of its core asset, REC-4881. The bank also raised its price target for Recursion from $10 to $11.

Analyst Priyanka Grover highlighted that REC-4881, currently in mid-stage trials for treating familial adenomatous polyposis (FAP), could achieve peak sales exceeding $1 billion in the U.S. alone, with a 60% probability of success.

Additionally, Grover emphasized Recursion’s second-most advanced candidate, REC-617, an oral CDK7 inhibitor showing antitumor potential in platinum-resistant ovarian cancer. Clinical development for this indication is progressing steadily.

"These clinical outcomes and partnerships with pharmaceutical firms further validate Recursion’s AI-driven pipeline, which has already generated over $500 million in milestone payments," Grover noted.

Recursion’s stock closed up 11.43% at $4.68 on Wednesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1108555751?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 14:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108555751","market":"hk","top_or_hot":-1,"title":"JPMorgan Upgrades Recursion Pharmaceuticals (RXRX.US) to \"Overweight,\" Citing Blockbuster Potential for Core Asset REC-4881","media":"Stock News","content":"<p>JPMorgan has upgraded Recursion Pharmaceuticals (RXRX.US) from \"Neutral\" to \"Overweight,\" citing the blockbuster sales potential of its core asset, REC-4881. The bank also raised its price target for Recursion from $10 to $11.</p>\n<p>Analyst Priyanka Grover highlighted that REC-4881, currently in mid-stage trials for treating familial adenomatous polyposis (FAP), could achieve peak sales exceeding $1 billion in the U.S. alone, with a 60% probability of success.</p>\n<p>Additionally, Grover emphasized Recursion’s second-most advanced candidate, REC-617, an oral CDK7 inhibitor showing antitumor potential in platinum-resistant ovarian cancer. Clinical development for this indication is progressing steadily.</p>\n<p>\"These clinical outcomes and partnerships with pharmaceutical firms further validate Recursion’s AI-driven pipeline, which has already generated over $500 million in milestone payments,\" Grover noted.</p>\n<p>Recursion’s stock closed up 11.43% at $4.68 on Wednesday.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JPMorgan Upgrades Recursion Pharmaceuticals (RXRX.US) to \"Overweight,\" Citing Blockbuster Potential for Core Asset REC-4881</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJPMorgan Upgrades Recursion Pharmaceuticals (RXRX.US) to \"Overweight,\" Citing Blockbuster Potential for Core Asset REC-4881\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-18 14:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>JPMorgan has upgraded Recursion Pharmaceuticals (RXRX.US) from \"Neutral\" to \"Overweight,\" citing the blockbuster sales potential of its core asset, REC-4881. The bank also raised its price target for Recursion from $10 to $11.</p>\n<p>Analyst Priyanka Grover highlighted that REC-4881, currently in mid-stage trials for treating familial adenomatous polyposis (FAP), could achieve peak sales exceeding $1 billion in the U.S. alone, with a 60% probability of success.</p>\n<p>Additionally, Grover emphasized Recursion’s second-most advanced candidate, REC-617, an oral CDK7 inhibitor showing antitumor potential in platinum-resistant ovarian cancer. Clinical development for this indication is progressing steadily.</p>\n<p>\"These clinical outcomes and partnerships with pharmaceutical firms further validate Recursion’s AI-driven pipeline, which has already generated over $500 million in milestone payments,\" Grover noted.</p>\n<p>Recursion’s stock closed up 11.43% at $4.68 on Wednesday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4611","symbol_name":"AI医疗","start_time":0,"source_url":"","article_id":"1108555751","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108555751","pubTimestamp":1766039483,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"JPMorgan has upgraded Recursion Pharmaceuticals (RXRX.US) from \"Neutral\" to \"Overweight,\" citing the blockbuster sales potential of its core asset, REC-4881. The bank also raised its price target for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4611":"AI医疗","BK4609":"英伟达持仓股","BK4539":"次新股","RXRX":"Recursion Pharmaceuticals, Inc.","BK4139":"生物科技","BK4548":"巴美列捷福持仓"},"translate_title":"摩根大通将Recursion Pharmaceuticals(RXRX.US)升级为“跑赢大盘”，理由是核心资产REC-4881具有重磅炸弹潜力","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RXRX":1},"content_text":"JPMorgan has upgraded Recursion Pharmaceuticals (RXRX.US) from \"Neutral\" to \"Overweight,\" citing the blockbuster sales potential of its core asset, REC-4881. The bank also raised its price target for Recursion from $10 to $11.\nAnalyst Priyanka Grover highlighted that REC-4881, currently in mid-stage trials for treating familial adenomatous polyposis (FAP), could achieve peak sales exceeding $1 billion in the U.S. alone, with a 60% probability of success.\nAdditionally, Grover emphasized Recursion’s second-most advanced candidate, REC-617, an oral CDK7 inhibitor showing antitumor potential in platinum-resistant ovarian cancer. Clinical development for this indication is progressing steadily.\n\"These clinical outcomes and partnerships with pharmaceutical firms further validate Recursion’s AI-driven pipeline, which has already generated over $500 million in milestone payments,\" Grover noted.\nRecursion’s stock closed up 11.43% at $4.68 on Wednesday.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1108555751","isCrawlerRequest":true}